Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

OBJECTIVES: The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with 'standard-of-care' (SoC)

METHODS: In the public hospital of Esine, northern Italy, 140 consecutive inpatients, with virologically and radiographically confirmed COVID-19 admitted in the period 5-19 March 2020, were treated with 'SoC' (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). They were compared with 122 consecutive inpatients, admitted between 19 March and 5 April 2020, treated with colchicine (1 mg/day) and SoC (antiviral drugs were stopped before colchicine, due to potential interaction)

RESULTS: Patients treated with colchicine had a better survival rate as compared with SoC at 21 days of follow-up (84.2% (SE=3.3%) vs 63.6% (SE=4.1%), p=0.001). Cox proportional hazards regression survival analysis showed that a lower risk of death was independently associated with colchicine treatment (HR=0.151 (95% CI 0.062 to 0.368), p<0.0001), whereas older age, worse PaO2/FiO2, and higher serum levels of ferritin at entry were associated with a higher risk

CONCLUSION: This proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19. Efficacy and safety must be determined in controlled clinical trials

Year of Publication: 2020
Contained in: Annals of the rheumatic diseases (30.07.2020)
All journal articles: Search for all articles in this journal
Language: English
Contributors: Scarsi, Mirko | Author
Piantoni, Silvia
Colombo, Enrico
Airó, Paolo
Richini, Donata
Miclini, Marco
Bertasi, Valeria
Bianchi, Marta
Bottone, Damiano
Civelli, Patrizia
Cotelli, Maria-Sofia
Damiolini, Ezio
Galbassini, Gloria
Gatta, Diego
Ghirardelli, Maria-Laura
Magri, Roberto
Malamani, Paola
Mendeni, Monia
Molinari, Stefano
Morotti, Andrea
Salada, Luisa
Turla, Marinella
Vender, Angiola
Tincani, Angela
Brucato, Antonio
Franceschini, Franco
Furloni, Roberto
Andreoli, Laura
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: Journal Article
anti-inflammatory agents, non-steroidal
antirheumatic agents
communicable diseases, imported
inflammation
therapeutics
ISSN: 1468-2060
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Revised 31.07.2020
published: Print-Electronic
Citation Status Publisher
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32732245
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1136/annrheumdis-2020-217712
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 04331nma a2200853 c 4500
001 NLM314004130
003 DE-601
005 20200731214053.0
007 cr uuu---uuuuu
008 200731s2020 000 0 eng d
024 7 |a 10.1136/annrheumdis-2020-217712  |2 doi 
028 5 2 |a pubmed20n1286.xml 
035 |a annrheumdis-2020-217712 
035 |a (DE-599)NLM32732245 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Scarsi, Mirko 
245 1 0 |a Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Revised 31.07.2020 
500 |a published: Print-Electronic 
500 |a Citation Status Publisher 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 
520 |a OBJECTIVES: The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with 'standard-of-care' (SoC) 
520 |a METHODS: In the public hospital of Esine, northern Italy, 140 consecutive inpatients, with virologically and radiographically confirmed COVID-19 admitted in the period 5-19 March 2020, were treated with 'SoC' (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). They were compared with 122 consecutive inpatients, admitted between 19 March and 5 April 2020, treated with colchicine (1 mg/day) and SoC (antiviral drugs were stopped before colchicine, due to potential interaction) 
520 |a RESULTS: Patients treated with colchicine had a better survival rate as compared with SoC at 21 days of follow-up (84.2% (SE=3.3%) vs 63.6% (SE=4.1%), p=0.001). Cox proportional hazards regression survival analysis showed that a lower risk of death was independently associated with colchicine treatment (HR=0.151 (95% CI 0.062 to 0.368), p<0.0001), whereas older age, worse PaO2/FiO2, and higher serum levels of ferritin at entry were associated with a higher risk 
520 |a CONCLUSION: This proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19. Efficacy and safety must be determined in controlled clinical trials 
611 2 7 |a Journal Article  |2 gnd 
655 7 |a anti-inflammatory agents, non-steroidal  |2 gnd 
655 7 |a antirheumatic agents  |2 gnd 
655 7 |a communicable diseases, imported  |2 gnd 
655 7 |a inflammation  |2 gnd 
655 7 |a therapeutics  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 |5 DE-601 
689 1 0 |a anti-inflammatory agents, non-steroidal 
689 1 1 |a antirheumatic agents 
689 1 2 |a communicable diseases, imported 
689 1 3 |a inflammation 
689 1 4 |a therapeutics 
689 1 |5 DE-601 
700 1 |a Piantoni, Silvia 
700 1 |a Colombo, Enrico 
700 1 |a Airó, Paolo 
700 1 |a Richini, Donata 
700 1 |a Miclini, Marco 
700 1 |a Bertasi, Valeria 
700 1 |a Bianchi, Marta 
700 1 |a Bottone, Damiano 
700 1 |a Civelli, Patrizia 
700 1 |a Cotelli, Maria-Sofia 
700 1 |a Damiolini, Ezio 
700 1 |a Galbassini, Gloria 
700 1 |a Gatta, Diego 
700 1 |a Ghirardelli, Maria-Laura 
700 1 |a Magri, Roberto 
700 1 |a Malamani, Paola 
700 1 |a Mendeni, Monia 
700 1 |a Molinari, Stefano 
700 1 |a Morotti, Andrea 
700 1 |a Salada, Luisa 
700 1 |a Turla, Marinella 
700 1 |a Vender, Angiola 
700 1 |a Tincani, Angela 
700 1 |a Brucato, Antonio 
700 1 |a Franceschini, Franco 
700 1 |a Furloni, Roberto 
700 1 |a Andreoli, Laura 
773 0 8 |i in  |t Annals of the rheumatic diseases  |g  (30.07.2020)  |w (DE-601)NLM000174114  |x 1468-2060 
856 4 1 |u http://dx.doi.org/10.1136/annrheumdis-2020-217712  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |j 2020  |b 30  |c 07